Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarlowe Regulatory News (MRL)

Share Price Information for Marlowe (MRL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 508.00
Bid: 506.00
Ask: 510.00
Change: 0.00 (0.00%)
Spread: 4.00 (0.791%)
Open: 508.00
High: 508.00
Low: 508.00
Prev. Close: 508.00
MRL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on COVID-19

31 Mar 2020 07:00

RNS Number : 1274I
Marlowe PLC
31 March 2020
 

31 March 2020

 

Marlowe plc

 

Update on COVID-19

 

Marlowe plc, the specialist services group focused on developing companies which assure safety and regulatory compliance, provides the following update on its trading and the impact of COVID-19.

 

Trading in the second half of the year has been strong and we expect to perform in line with expectations for the year to 31 March 2020, despite increasingly challenging conditions in recent weeks. Given the essential nature of our services, we remain confident that our resilient business model positions us more favourably than most sectors of the economy to both operate under the current COVID-19 restrictions and to benefit from a wider recovery in activity once these restrictions are eased.

 

The health, safety and wellbeing of our employees and our customers are our overriding priorities and we have put in place appropriate safety protocols across the Group. The services that we deliver have been largely designated as critical under current Government guidance, enabling us to play our part in helping to keep our clients - which include healthcare facilities, food production and care homes - compliant with health & safety laws and regulations, and their premises safe and operational, during these unprecedented times.

 

Following the enhanced Government and Public Health England guidance issued on 23 March, we have seen some impact where staff are unable to gain access to sites in order to complete work and, whilst we are unable to predict the long-term impact of these measures with any degree of certainty, it is likely that we will see some impact on our operations and performance in the first quarter of our new financial year. However, given the regulatory-driven nature of our business, we expect the majority of any lost revenue in this period to be recovered once normal site access resumes. Parts of our Group, including our employment law, HR compliance, occupational health and certain water hygiene activities, are experiencing an increased demand for services.

 

We have a strong balance sheet, with the Group's debt facility comprising a £45m revolving credit facility, and net debt at 30 September 2019 (excluding the effects of the adoption of IFRS 16) was £19.6m. As such, we are confident that we have sufficient funding capacity to manage a wide range of scenarios. To prepare for the possibility that current restrictions remain in effect beyond the immediate term, and to minimise any concomitant impact on our business, we are implementing cost reduction measures across the Group to protect profitability and preserve cash.

 

Alex Dacre, Chief Executive of Marlowe plc, said:

 

"We are pleased to report a strong second half to our financial year despite the challenging conditions in the final few weeks. Whilst restrictions related to COVID-19 will have an impact on our ability to complete some of our scheduled work in the short-term, we expect that a large proportion of this revenue will be deferred to later in our new financial year.

 

"Our outlook beyond COVID-19 is positive, with growing demand for the type of regulated safety and compliance services that our Group delivers. We will provide a further update as and when there is greater clarity on the impact of COVID-19 on our trading environment."

 

For further information:

 

Marlowe plc

www.marloweplc.com

Alex Dacre, Chief Executive

Tel: +44 (0) 203 813 8498

Mark Adams, Group Finance Director

IR@marloweplc.com

Cenkos Securities plc (Nominated Adviser and Joint Broker)

Nicholas Wells

Tel: +44 (0)20 7397 8900

Ben Jeynes

Harry Hargreaves

Berenberg (Joint Broker)

Ben Wright

Tel: +44 (0)20 3207 7800

Mark Whitmore

FTI Consulting

Nick Hasell

Tel: +44 (0)20 3727 1340

Alex Le May

 

About Marlowe plc

Marlowe is a UK leader in specialist services which assure safety and regulatory compliance, whilst managing risk for businesses across the country. The company was formed to create sustainable shareholder value through the acquisition and development of businesses that provide regulated inspection, testing and compliance services. It is focused on health & safety, employment law compliance, fire safety, security, water treatment & hygiene, air quality and occupational health services - all of which are vital to the wellbeing of its customers operations and are invariably governed by regulation. Marlowe currently provides services to over 15% of Britain's commercial premises and is increasingly attractive to customers who require a single outsourced, nationwide, provider of a comprehensive range of regulated compliance and safety services. Our customers can be found in most office complexes, high streets & leisure facilities, manufacturing plants and industrial estates, and include SMEs, local authorities, facilities management providers, multi-site NHS trusts and FTSE 100 companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDEAPDEDEEEEFA
Date   Source Headline
30th Apr 20247:00 amRNSTotal Voting Rights
8th Apr 20242:54 pmRNSHolding(s) in Company
28th Mar 20247:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
26th Mar 20244:45 pmRNSBlock listing Interim Review
18th Mar 20247:00 amRNSBoard Changes; Update re: Returns of Capital
26th Feb 20247:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
22nd Feb 20247:00 amRNSDisposal and Directorate Change
15th Jan 202410:23 amRNSChange of Nominated Adviser and Joint Broker
30th Nov 20237:00 amRNSTotal Voting Rights
28th Nov 20237:00 amRNSInterim results for the six months to 30 Sept 2023
23rd Nov 20237:00 amRNSNotice of Interim Results
31st Oct 20234:30 pmRNSTotal Voting Rights
27th Sep 20235:18 pmRNSHolding(s) in Company
26th Sep 20233:23 pmRNSBlock Admission
13th Sep 20236:15 pmRNSResult of AGM
13th Sep 20237:00 amRNSAnnual General Meeting and Trading Update
4th Sep 20237:00 amRNSHolding(s) in Company
8th Aug 20237:00 amRNSExercise of Share Options and Total Voting Rights
7th Aug 20237:45 amRNSResponse to Speculation
4th Aug 20233:50 pmRNSHolding(s) in Company
3rd Aug 20235:25 pmRNSHolding(s) in Company
31st Jul 20233:30 pmRNSIssue of Equity and Total Voting Rights
26th Jul 20237:00 amRNSAcquisition of IMSM
18th Jul 202312:15 pmRNSCapital Reduction Effective
13th Jul 20232:00 pmRNSPublication of Notice of AGM and Annual Report
29th Jun 20237:00 amRNSPreliminary results
26th Jun 20237:00 amRNSNotice of Full Year Results
23rd Jun 20234:56 pmRNSHolding(s) in Company
19th Jun 202311:06 amRNSResult of General Meeting
5th Jun 20239:31 amRNSHolding(s) in Company
2nd Jun 20232:51 pmRNSPosting of Circular and Notice of General Meeting
2nd Jun 202312:36 pmRNSHolding(s) in Company
18th Apr 20231:45 pmRNSHolding(s) in Company
29th Mar 20237:00 amRNSCapital Markets Day Replay
28th Mar 20237:00 amRNSCapital Markets Day and Trading Update
7th Mar 20237:00 amRNSNotice of Capital Markets Event
28th Feb 20232:20 pmRNSHolding(s) in Company
26th Jan 20231:46 pmRNSHolding(s) in Company
5th Jan 20237:00 amRNSNotice of Capital Markets Event
2nd Dec 20229:00 amRNSNotice of Investor Presentation
1st Dec 202210:34 amRNSDirector/PDMR Shareholding
1st Dec 20229:00 amRNSDirector/PDMR Shareholding
24th Nov 20222:14 pmRNSDirector/PDMR Shareholding
24th Nov 20221:48 pmRNSDirector/PDMR Shareholding
23rd Nov 20227:00 amRNSHalf-year Report
21st Nov 202212:54 pmRNSExercise of Share Options and Total Voting Rights
17th Nov 20227:00 amRNSNotice of Interim Results
2nd Nov 20225:08 pmRNSHolding(s) in Company
19th Oct 202210:40 amRNSExercise of Share Options and Total Voting Rights
14th Oct 20223:12 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.